Lyell Immunopharma (LYEL)
Lyell Immunopharma on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
1.4M
Short interest
settlement 2026-10-15
7.8
Days to cover
+0.4 days vs prior
44.8%
Short share of volume
2026-11-02
80
Fails to deliver
settlement 2026-10-13
Wed 11 Nov
Next earnings
estimated date
-$215K
Insider flow, 90 days
0 buys, 9 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in LYEL is 1,398,232 shares, up 210,330 shares over the last month. Over the last 48 readings it ranged from 132,974 shares (15 August 2025) to 12,397,650 shares (15 January 2025). At the reported average volume of 178K shares a day that is 7.8 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/lyel" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 1,398,232 | +10.7% | 178,106 | 7.85 |
| 2026-09-30 | 1,263,394 | +6.4% | 170,775 | 7.40 |
| 2026-09-15 | 1,187,902 | +5.0% | 98,363 | 12.08 |
| 2026-08-31 | 1,131,628 | -1.7% | 127,223 | 8.89 |
| 2026-08-14 | 1,151,707 | -6.5% | 183,855 | 6.26 |
| 2026-07-31 | 1,231,583 | +0.9% | 142,256 | 8.66 |
| 2026-07-15 | 1,220,497 | -0.2% | 182,227 | 6.70 |
| 2026-06-30 | 1,223,220 | -7.1% | 355,339 | 3.44 |
| 2026-06-15 | 1,316,562 | -2.7% | 136,926 | 9.62 |
| 2026-05-29 | 1,353,275 | +1.0% | 83,489 | 16.21 |
| 2026-05-15 | 1,340,406 | -0.3% | 57,657 | 23.25 |
| 2026-04-30 | 1,344,189 | +8.9% | 71,577 | 18.78 |
| 2026-04-15 | 1,234,370 | +8.4% | 102,547 | 12.04 |
| 2026-03-31 | 1,138,296 | +21.1% | 89,076 | 12.78 |
| 2026-03-13 | 940,269 | +15.3% | 109,417 | 8.59 |
| 2026-02-27 | 815,248 | +37.7% | 106,872 | 7.63 |
| 2026-02-13 | 592,027 | +13.6% | 94,235 | 6.28 |
| 2026-01-30 | 521,115 | +27.9% | 85,589 | 6.09 |
| 2026-01-15 | 407,278 | +69.2% | 102,840 | 3.96 |
| 2025-12-31 | 240,730 | +46.4% | 152,163 | 1.58 |
| 2025-12-15 | 164,482 | +1.7% | 67,437 | 2.44 |
| 2025-11-28 | 161,792 | -0.8% | 48,226 | 3.35 |
| 2025-11-14 | 163,125 | -1.9% | 27,623 | 5.91 |
| 2025-10-31 | 166,193 | -9.6% | 25,429 | 6.54 |
| 2025-10-15 | 183,877 | -21.1% | 37,672 | 4.88 |
| 2025-09-30 | 233,067 | +43.3% | 89,521 | 2.60 |
| 2025-09-15 | 162,607 | +11.6% | 28,140 | 5.78 |
| 2025-08-29 | 145,675 | +9.6% | 23,222 | 6.27 |
| 2025-08-15 | 132,974 | -29.3% | 33,634 | 3.95 |
| 2025-07-31 | 188,200 | -22.8% | 94,993 | 1.98 |
| 2025-07-15 | 243,764 | -6.5% | 46,804 | 5.21 |
| 2025-06-30 | 260,638 | -26.6% | 233,530 | 1.12 |
| 2025-06-13 | 355,342 | -96.7% | 427,933 | 1.00 |
| 2025-05-30 | 10,630,321 | +9.5% | 559,912 | 18.99 |
| 2025-05-15 | 9,707,213 | +71.4% | 683,606 | 14.20 |
| 2025-04-30 | 5,664,643 | +0.4% | 680,555 | 8.32 |
| 2025-04-15 | 5,642,485 | -1.2% | 712,414 | 7.92 |
| 2025-03-31 | 5,711,632 | -4.4% | 986,364 | 5.79 |
| 2025-03-14 | 5,977,013 | -26.1% | 746,946 | 8.00 |
| 2025-02-28 | 8,087,277 | -16.2% | 1,022,911 | 7.91 |
| 2025-02-14 | 9,647,386 | -16.3% | 1,789,986 | 5.39 |
| 2025-01-31 | 11,525,095 | -7.0% | 737,608 | 15.62 |
| 2025-01-15 | 12,397,650 | +0.7% | 855,797 | 14.49 |
| 2024-12-31 | 12,314,391 | +12.1% | 1,369,810 | 8.99 |
| 2024-12-13 | 10,985,361 | +16.2% | 1,268,323 | 8.66 |
| 2024-11-29 | 9,451,540 | -1.6% | 1,596,859 | 5.92 |
| 2024-11-15 | 9,604,319 | -13.8% | 1,321,558 | 7.27 |
| 2024-10-31 | 11,138,482 | +3.5% | 2,437,224 | 4.57 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of LYEL volume is 44.8%, down 34.1 points over the last five sessions. Over the last 30 readings it ranged from 8.1% (22 September 2026) to 79.1% (15 October 2026). The latest reading is 6.3 points below the 30-session average of 51.1%, on 32K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 14K | 32K | 44.8% | 0 |
| 2026-10-30 | 20K | 42K | 46.0% | 0 |
| 2026-10-29 | 36K | 52K | 69.9% | 0 |
| 2026-10-28 | 18K | 48K | 37.8% | 2 |
| 2026-10-27 | 17K | 40K | 42.1% | 0 |
| 2026-10-26 | 24K | 30K | 78.9% | 0 |
| 2026-10-23 | 25K | 48K | 50.9% | 0 |
| 2026-10-22 | 18K | 36K | 50.3% | 0 |
| 2026-10-21 | 18K | 45K | 40.5% | 0 |
| 2026-10-20 | 44K | 61K | 72.0% | 0 |
| 2026-10-19 | 30K | 56K | 53.5% | 12 |
| 2026-10-16 | 42K | 69K | 60.4% | 0 |
| 2026-10-15 | 130K | 165K | 79.1% | 0 |
| 2026-10-14 | 99K | 165K | 59.7% | 5,116 |
| 2026-10-13 | 34K | 60K | 56.0% | 2,259 |
| 2026-10-12 | 27K | 43K | 63.0% | 4 |
| 2026-10-09 | 17K | 33K | 51.5% | 0 |
| 2026-10-08 | 31K | 69K | 44.7% | 0 |
| 2026-10-07 | 19K | 54K | 35.6% | 0 |
| 2026-10-06 | 29K | 55K | 53.5% | 0 |
| 2026-10-05 | 20K | 57K | 34.6% | 0 |
| 2026-10-02 | 20K | 46K | 44.6% | 0 |
| 2026-10-01 | 18K | 36K | 50.0% | 0 |
| 2026-09-30 | 25K | 51K | 49.1% | 0 |
| 2026-09-29 | 28K | 56K | 49.7% | 0 |
| 2026-09-28 | 25K | 47K | 53.2% | 0 |
| 2026-09-25 | 17K | 34K | 51.0% | 0 |
| 2026-09-24 | 34K | 66K | 51.5% | 0 |
| 2026-09-23 | 35K | 69K | 50.9% | 8 |
| 2026-09-22 | 7K | 88K | 8.1% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in LYEL is 80 shares, up 63 shares over the last settlement date. Over the last 30 readings it ranged from 8 shares (3 August 2026) to 56,949 shares (20 April 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 80 | $8.27 | $662 |
| 2026-09-17 | 17 | $10.78 | $183 |
| 2026-09-16 | 18 | $10.91 | $196 |
| 2026-09-15 | 306 | $11.33 | $3K |
| 2026-09-10 | 18 | $12.88 | $232 |
| 2026-08-31 | 1,558 | $14.53 | $23K |
| 2026-08-27 | 31 | $14.80 | $459 |
| 2026-08-21 | 18 | $15.35 | $276 |
| 2026-08-20 | 37 | $15.76 | $583 |
| 2026-08-19 | 18 | $15.79 | $284 |
| 2026-08-18 | 18 | $13.55 | $244 |
| 2026-08-17 | 18 | $13.95 | $251 |
| 2026-08-14 | 18 | $13.74 | $247 |
| 2026-08-13 | 17 | $14.17 | $241 |
| 2026-08-03 | 8 | $12.94 | $104 |
| 2026-07-28 | 79 | $12.96 | $1K |
| 2026-07-27 | 4,656 | $12.63 | $59K |
| 2026-07-21 | 19,575 | $12.92 | $253K |
| 2026-07-16 | 171 | $14.26 | $2K |
| 2026-07-09 | 246 | $15.40 | $4K |
| 2026-06-22 | 334 | $12.74 | $4K |
| 2026-06-18 | 2,495 | $12.52 | $31K |
| 2026-06-15 | 142 | $13.50 | $2K |
| 2026-06-04 | 13,798 | $12.57 | $173K |
| 2026-05-08 | 900 | $20.06 | $18K |
| 2026-05-07 | 1,610 | $20.85 | $34K |
| 2026-04-20 | 56,949 | $24.01 | $1.4M |
| 2026-04-15 | 50 | $23.37 | $1K |
| 2026-03-24 | 1,644 | $19.55 | $32K |
| 2026-03-23 | 46 | $19.12 | $880 |
Insider trades
SEC Form 4, newest first. JSONInsiders at LYEL reported 9 open-market sells worth $215K in the last 90 days and no open-market buys. Latest filing: Aguirre Jarrad Mattieu (Chief Medical Officer) on 2026-10-12.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | Aguirre Jarrad Mattieu | Chief Medical Officer | Sell | 422 | $8.63 | $4K | 20K |
| 2026-09-10 | Shook David | Chief Medical Officer | Sell | 500 | $12.70 | $6K | 20K |
| 2026-08-21 | Seely Lynn | President and CEO | Sell | 10K | $15.54 | $149K | 64K |
| 2026-08-21 | Lee Gary K. | Chief Scientific Officer | Sell | 1K | $15.54 | $23K | 16K |
| 2026-08-21 | Hill Stephen J. | Chief Operating Officer | Sell | 989 | $15.54 | $15K | 17K |
| 2026-08-10 | Seely Lynn | President and CEO | Sell | 390 | $14.34 | $6K | 73K |
| 2026-08-10 | Lee Gary K. | Chief Scientific Officer | Sell | 131 | $14.34 | $2K | 18K |
| 2026-08-10 | Hill Stephen J. | Chief Operating Officer | Sell | 89 | $14.34 | $1K | 18K |
| 2026-08-10 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 621 | $14.34 | $9K | 15K |
| 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Other transaction | 44K | $0.00 | $0 | 2.8M |
| 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Other transaction | 39K | $0.00 | $0 | 2.8M |
| 2026-07-17 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Sell | 10 | $13.70 | $137 | 2.9M |
| 2026-07-16 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Sell | 10 | $13.73 | $137 | 2.9M |
| 2026-06-29 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Other transaction | 76K | $0.00 | $0 | 2.9M |
| 2026-06-15 | Innovative Cellular Therapeutics Holdings Ltd | TenPercentOwner | Other transaction | 67K | $0.00 | $0 | 2.9M |
| 2026-06-10 | Shook David | Chief Medical Officer | Sell | 2K | $12.64 | $25K | 21K |
| 2026-05-11 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 217 | $18.91 | $4K | 15K |
| 2026-05-11 | Hill Stephen J. | Chief Operating Officer | Sell | 89 | $18.92 | $2K | 18K |
| 2026-05-11 | Lee Gary K. | Chief Scientific Officer | Sell | 130 | $18.92 | $2K | 18K |
| 2026-05-11 | Seely Lynn | President and CEO | Sell | 388 | $18.91 | $7K | 74K |
| 2026-03-06 | BERNS PAUL L | TenPercentOwner | Buy | 488K | $25.61 | $12.5M | 1.4M |
| 2026-03-06 | ARCH Venture Partners IX Overage, L.P. | TenPercentOwner | Buy | 488K | $25.61 | $12.5M | 1.4M |
| 2026-03-06 | ARCH Venture Fund XIII, L.P. | 10% owner | Buy | 488K | $25.61 | $12.5M | 1.4M |
| 2026-03-06 | ARCH Venture Partners IX, LLC | 10% owner | Buy | 488K | $25.61 | $12.5M | 1.4M |
| 2026-02-11 | Seely Lynn | President and CEO | Sell | 7K | $23.39 | $174K | 74K |
| 2026-02-11 | Lee Gary K. | Chief Scientific Officer | Sell | 2K | $23.39 | $39K | 17K |
| 2026-02-11 | Hill Stephen J. | Chief Operating Officer | Sell | 1K | $23.39 | $29K | 18K |
| 2026-02-10 | Seely Lynn | President and CEO | Sell | 438 | $23.12 | $10K | 82K |
| 2026-02-10 | Lee Gary K. | Chief Scientific Officer | Sell | 147 | $23.12 | $3K | 19K |
| 2026-02-10 | Hill Stephen J. | Chief Operating Officer | Sell | 109 | $23.12 | $3K | 19K |
| 2026-02-10 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 254 | $23.12 | $6K | 16K |
| 2026-02-10 | Bulis Veronica Sanchez | VP, Corporate Controller | Grant | 9K | $0.00 | $0 | 16K |
| 2026-02-09 | Seely Lynn | President and CEO | Grant | 20K | $0.00 | $0 | 82K |
| 2026-02-09 | Lee Gary K. | Chief Scientific Officer | Grant | 4K | $0.00 | $0 | 19K |
| 2026-02-09 | Hill Stephen J. | Chief Operating Officer | Grant | 4K | $0.00 | $0 | 19K |
| 2025-12-30 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 936 | $32.32 | $30K | 7K |
| 2025-12-24 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 1K | $38.67 | $44K | 8K |
| 2025-11-10 | Seely Lynn | President and CEO | Sell | 412 | $16.11 | $7K | 67K |
| 2025-11-10 | Lee Gary K. | Chief Scientific Officer | Sell | 138 | $16.16 | $2K | 15K |
| 2025-11-10 | Hill Stephen J. | Chief Operating Officer | Sell | 95 | $16.12 | $2K | 16K |
| 2025-11-10 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 239 | $16.10 | $4K | 9K |
| 2025-08-21 | Seely Lynn | President and CEO | Sell | 7K | $10.54 | $77K | 68K |
| 2025-08-21 | Newton Charles W. | Chief Financial Officer | Sell | 1K | $10.54 | $15K | 15K |
| 2025-08-21 | Lee Gary K. | Chief Scientific Officer | Sell | 1K | $10.54 | $15K | 16K |
| 2025-08-21 | Hill Stephen J. | Chief Operating Officer | Sell | 1K | $10.54 | $11K | 16K |
| 2025-08-20 | Seely Lynn | President and CEO | Grant | 40K | $0.00 | $0 | 75K |
| 2025-08-20 | Newton Charles W. | Chief Financial Officer | Grant | 8K | $0.00 | $0 | 17K |
| 2025-08-20 | Lee Gary K. | Chief Scientific Officer | Grant | 8K | $0.00 | $0 | 17K |
| 2025-08-20 | Hill Stephen J. | Chief Operating Officer | Grant | 8K | $0.00 | $0 | 17K |
| 2025-08-12 | Seely Lynn | President and CEO | Sell | 406 | $10.34 | $4K | 35K |
| 2025-08-12 | Newton Charles W. | Chief Financial Officer | Sell | 136 | $10.34 | $1K | 9K |
| 2025-08-12 | Lee Gary K. | Chief Scientific Officer | Sell | 136 | $10.34 | $1K | 9K |
| 2025-08-12 | Hill Stephen J. | Chief Operating Officer | Sell | 94 | $10.34 | $972 | 9K |
| 2025-08-11 | Seely Lynn | President and CEO | Sell | 391 | $10.53 | $4K | 35K |
| 2025-08-11 | Newton Charles W. | Chief Financial Officer | Sell | 131 | $10.53 | $1K | 9K |
| 2025-08-11 | Lee Gary K. | Chief Scientific Officer | Sell | 131 | $10.53 | $1K | 9K |
| 2025-08-11 | Hill Stephen J. | Chief Operating Officer | Sell | 91 | $10.53 | $958 | 9K |
| 2025-06-09 | Shook David | Chief Medical Officer | Grant | 22K | $0.00 | $0 | 22K |
| 2025-03-31 | BRAWLEY OTIS W | Director | Buy | 36K | $0.56 | $20K | 36K |
| 2025-03-21 | Ramachandra Sumant | Director | Buy | 200K | $0.58 | $116K | 200K |
| 2025-03-17 | Newton Charles W. | Chief Financial Officer | Buy | 200K | $0.56 | $112K | 200K |
| 2025-03-14 | Seely Lynn | President and CEO | Buy | 175K | $0.61 | $107K | 713K |
| 2025-03-14 | Klausner Richard | Director | Buy | 158K | $0.60 | $95K | 843K |
| 2025-02-10 | Lee Gary K. | Chief Scientific Officer | Grant | 113K | $0.00 | $0 | 177K |
| 2025-02-10 | Newton Charles W. | Chief Financial Officer | Grant | 113K | $0.00 | $0 | 173K |
| 2025-02-10 | Hill Stephen J. | Chief Operating Officer | Grant | 113K | $0.00 | $0 | 173K |
| 2025-02-10 | Seely Lynn | President and CEO | Grant | 338K | $0.00 | $0 | 538K |
| 2025-02-10 | Lang Matthew | Chief Business Officer | Grant | 113K | $0.00 | $0 | 163K |
| 2024-02-09 | Seely Lynn | President and CEO | Grant | 200K | $0.00 | $0 | 200K |
| 2024-02-09 | Newton Charles W. | Chief Financial Officer | Grant | 40K | $0.00 | $0 | 49K |
| 2024-02-09 | Lee Gary K. | Chief Scientific Officer | Grant | 40K | $0.00 | $0 | 53K |
| 2024-02-09 | Hill Stephen J. | Chief Operating Officer | Grant | 40K | $0.00 | $0 | 49K |
| 2024-02-09 | Lang Matthew | Chief Business Officer | Grant | 50K | $0.00 | $0 | 50K |
| 2023-08-15 | Klausner Richard | Director | Sell | 58K | $2.28 | $132K | 931K |
| 2022-09-23 | Klausner Richard | Director | Sell | 11K | $6.40 | $71K | 989K |
| 2022-09-08 | Bishop Hans Edgar | Director | Exercise or conversion | 145K | $0.10 | $15K | 4.7M |
| 2022-02-23 | Bishop Hans Edgar | Director | Exercise or conversion | 993K | $0.10 | $99K | 4.5M |
| 2021-12-14 | FRIEDMAN CATHY | Director | Other transaction | 219K | $0.00 | $0 | 236K |
| 2021-12-14 | FRIEDMAN CATHY | Director | Other transaction | 3.8M | $0.00 | $0 | 0 |
| 2021-06-21 | NELSEN ROBERT | Director, 10% owner | Conversion | 18.2M | price not stated in the filing | not stated | 18.2M |
| 2021-06-21 | FRIEDMAN CATHY | Director | Conversion | 3.8M | price not stated in the filing | not stated | 3.8M |
| 2021-06-21 | FRIEDMAN CATHY | Director | Buy | 18K | $17.00 | $300K | 18K |
| 2021-06-21 | Bishop Hans Edgar | Director | Conversion | 547K | price not stated in the filing | not stated | 3.5M |
| 2021-06-21 | Klausner Richard | Executive Chairman | Conversion | 3.8M | price not stated in the filing | not stated | 3.8M |
| 2021-06-21 | NELSEN ROBERT | Director,TenPercentOwner | Conversion | 18.2M | price not stated in the filing | not stated | 18.2M |
| 2021-06-21 | ARCH Venture Fund IX, L.P. | TenPercentOwner | Conversion | 18.2M | price not stated in the filing | not stated | 18.2M |
| 2021-06-21 | GLAXOSMITHKLINE PLC | TenPercentOwner | Conversion | 30.3M | price not stated in the filing | not stated | 30.3M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON20 holders report 5% or more of LYEL in their latest filing, all on Schedule 13G (passive). The largest reported stake is ARCH Venture Partners IX, LLC at 13.9% of the class (3,247,162 shares), filed 2026-05-15 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 4 | James B. Tananbaumindividual | 653K | 2.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Foresite Capital Fund V, L.P.partnership | 476K | 1.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Foresite Capital Management V, LLCother entity | 476K | 1.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Foresite Capital Opportunity Fund V, L.P.partnership | 177K | 0.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Foresite Capital Opportunity Management V, LLCother entity | 177K | 0.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Foresite Capital Fund IV, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Foresite Capital Management IV, LLCother entity | 0 | 0.0% | 2026-06-30 |
| 2026-06-18 | 13G/Ano. 1 | Innovative Cellular Therapeutics Holdings Limitedother entity | 3.0M | 12.3% | 2026-05-18 |
| 2026-05-15 | 13G/Ano. 4 | ARCH Venture Partners IX, LLCother entity | 3.2M | 13.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | ARCH Venture Partners IX Overage, L.P.partnership | 3.2M | 13.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | ARCH Venture Partners IX, L.P.partnership | 3.2M | 13.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | ARCH Venture Fund IX Overage, L.P.partnership | 3.2M | 13.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | ARCH Venture Fund XIII, L.P.partnership | 3.2M | 13.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | ARCH Venture Fund IX, L.P.partnership | 3.2M | 13.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Steven Gillisindividual | 3.2M | 13.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Kristina Burowindividual | 3.2M | 13.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Robert Nelsenindividual | 3.2M | 13.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Keith Crandellindividual | 3.2M | 13.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | ARCH Venture Partners XIII, LLCother entity | 3.2M | 13.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | ARCH Venture Partners XIII, L.P.partnership | 3.2M | 13.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Clinton Bybeeindividual | 1.8M | 7.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Paul Bernsindividual | 1.4M | 6.1% | 2026-03-31 |
| 2026-05-11 | 13G/Ano. 1 | Milky Way Investments Group Ltd.corporation | 1.0M | 4.3% | 2026-03-31 |
| 2026-05-11 | 13G/Ano. 1 | MWG Caph Ltdcorporation | 1.0M | 4.3% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 1 | Explore Investments LLCother entity | 1.5M | 6.6% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 1 | Jeffrey P. Bezosindividual | 1.5M | 6.6% | 2026-03-31 |
| 2026-04-21 | 13G | EULER FUND, L.P.partnership | 1.4M | 6.7% | 2026-03-06 |
| 2026-04-21 | 13G | Antonis Indianosindividual | 1.4M | 6.7% | 2026-03-06 |
| 2026-04-21 | 13G | Euler Managers Limitedcorporation | 1.4M | 6.7% | 2026-03-06 |
| 2025-11-12 | 13G/Ano. 1 | Newton (PTC) Limitedcorporation | 755K | 3.9% | 2025-09-30 |
| 2025-11-12 | 13G/Ano. 1 | Orland Properties Limitedcorporation | 755K | 3.9% | 2025-09-30 |
| 2025-11-12 | 13G/Ano. 1 | Gemini GP Limitedcorporation | 755K | 3.9% | 2025-09-30 |
| 2025-11-12 | 13G/Ano. 1 | Gemini Investments, L.P.partnership | 755K | 3.9% | 2025-09-30 |
13F holders
Tracked managers holding LYEL at their latest 13F. JSON5 of the 30 tracked managers held LYEL at their latest 13F, $8.4M in total at quarter-end prices. Millennium Management is the largest at $5.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 367K | $5.2M | 0.00% | -91K |
| Renaissance Technologies | 2026-06-30 | 130K | $1.8M | 0.00% | +14K |
| Two Sigma Investments | 2026-06-30 | 53K | $744K | 0.00% | +41K |
| Point72 Asset Management | 2026-06-30 | 26K | $366K | 0.00% | +5K |
| Citadel Advisors | 2026-06-30 | 19K | $263K | 0.00% | -363K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Lyell Immunopharma in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Lyell Immunopharma (LYEL), SEC CIK 1806952, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-12.JSON and CSV
- Company record
- EDGAR filing index for CIK 1806952Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of LYEL is sold short?
1,398,232 shares were held short at the 2026-10-15 settlement, 7.8 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is LYEL's daily short volume?
On 2026-11-02, 14,369 of the 32,090 LYEL shares reported to FINRA were sold short, 44.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does LYEL have fails to deliver?
The SEC's latest file shows 80 LYEL shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are LYEL insiders buying or selling?
Insiders at LYEL reported 9 open-market sells worth $215K in the last 90 days and no open-market buys. Latest filing: Aguirre Jarrad Mattieu (Chief Medical Officer) on 2026-10-12.
Who owns 5% or more of LYEL?
20 holders report 5% or more of LYEL in their latest filing, all on Schedule 13G (passive). The largest reported stake is ARCH Venture Partners IX, LLC at 13.9% of the class (3,247,162 shares), filed 2026-05-15 for an event on 2026-03-31.
Which tracked 13F managers own LYEL?
5 of the 30 tracked 13F managers held LYEL shares at their latest filing, $8.4M in all. The largest: Izzy Englander's Millennium Management (367K shares, $5.2M), Renaissance Technologies (130K shares, $1.8M), Two Sigma Investments (53K shares, $744K), Steve Cohen's Point72 Asset Management (26K shares, $366K), Ken Griffin's Citadel Advisors (19K shares, $263K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.